Remove 2023 Remove FDA Remove Pharmaceutical manufacturing Remove Safety
article thumbnail

FDA warning letters highlight data integrity issues

European Pharmaceutical Review

FDA inspections Identification of data integrity deviations Of the 70 Warning Letters issued by the US Food and Drug Administration (FDA) so far in 2024, three have identified data integrity issues at pharmaceutical manufacturing sites outside the US.

FDA 89
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 3) policing anticompetitive settlements between competing drug manufacturers. Citizen Petitions before the FDA. 5) monitoring access to biosimilars. Senate Bill 562 (S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Everything You Need to Know About Market Access in China

PM360

market (source: IQVIA MIDAS, May 2023). At the same time, a “drug lag” persists in China for global pharmaceutical companies’ products. billion people in 2023). Pharmaceutical companies can sell drugs with free pricing in the GBA and Hainan Boao after obtaining foreign approval (e.g., in the U.S.

Marketing 105
article thumbnail

Biosimilars Market Set for Biggest Year Yet in 2023

PM360

biosimilars market to date, the first of eight FDA-approved Humira (adalimumab) biosimilars launched in the United States in January after years of regulatory delays. Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

Needles cause patients pain, anxiety, pose safety risks, and for some people receiving injection therapy is a traumatic experience. The FDA 510(k) submission is expected to take place in Quarter 3 2023. Pharmaceutical manufacturers can customize the solution based on the brand’s objectives and patient population’s needs.